CNMD Earnings Prediction
The chart below shows how CNMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CNMD sees a +2.09% change in stock price 10 days leading up to the earnings, and a -2.68% change 10 days following the report. On the earnings day itself, the stock moves by +1.04%. This data can give you a slight idea of what to expect for the next quarter's release.
CNMD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
345.94M
5.78%
9.23%
Gross Margin
57.33%
2.93%
1.43%
Operating Margin
15.18%
-1.11%
-26.84%
Net Margin
9.76%
-3.46%
-36.91%
EPS
1.08
2.86%
-31.21%
No Data Available
CNMD Earnings Analysis
Conmed Corp Corporation (CNMD.N) Earnings Conference Call
Positive
Q4 Sales Increase: Total sales for Q4 2024 were $345.9 million, representing a year-over-year increase of 5.8% as reported and 6% in constant currency.
Q4 Adjusted Net Income Growth: Adjusted net income for Q4 2024 was $41.8 million, an increase of 26.2% year-over-year, with adjusted diluted net earnings per share of $1.34, up 26.4% year-over-year.
Adjusted Net Income Growth: For the full year 2024, adjusted net income was $129.9 million, a 20% increase compared to 2023, with adjusted diluted net earnings per share of $4.17, a 20.9% increase year-over-year.
Operating Margin Improvement: Adjusted operating margin for Q4 2024 was 18.6%, an increase of 280 basis points over the prior year quarter, while the full year adjusted operating margin improved by 150 basis points to 15.5%.
Operating Cash Flow Growth: Cash flow provided from operations for the full year 2024 was $167.0 million, compared to $125.3 million in 2023, reflecting a strong growth of 33.2% in operating cash flow.
Negative
Orthopedic Sales Performance: Sales growth for the Orthopedic business was only 2.4% in Q4 2024 and 2.5% for the full year, significantly below market potential due to ongoing supply challenges.
Decline in Cash Flow: Cash flow from operations decreased to $43.3 million in Q4 2024, down from $56.4 million in Q4 2023, indicating a decline in operational efficiency despite overall sales growth.
Cash Balance Decline: The company’s cash balance dropped to $24.5 million at year-end 2024, down from $38.5 million at the end of Q3 2024, reflecting potential liquidity concerns.
Cautious Revenue Growth Outlook: Projected revenue growth for 2025 is only between 4% and 6%, which is at the low end of the expected range, indicating a cautious outlook for the upcoming year.
Tariff Impact on Profitability: Potential tariffs from the new administration could impose an additional $45 million in costs, creating significant uncertainty and potential financial strain on future profitability.
CNMD FAQs
How does CNMD typically perform around its earnings report dates?
Is Conmed Corp (CNMD) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CNMD Earning Call Sentiment
CONMED Corporation (NYSE:CNMD) Q4 2024 Earnings Call Transcript
CNMD.N
-1.42%Positive
The earnings report shows strong financial performance with record high revenues and significant improvements in margins. Despite some supply chain challenges, the company has engaged a consulting firm to address these issues. The AirSeal platform continues to show strong demand and growth prospects. Management's cautious guidance is balanced by the potential for upside, and the company is actively managing debt. The market cap suggests a moderate reaction, leading to a positive outlook for the stock price over the next two weeks.
